Herpes Zoster Vaccination
2
조회
0
다운로드
4
인용
0
참고문헌
키워드
초록
Varicella (chickenpox) is a highly contagious airborne disease caused by primary infection with the varicella zoster virus (VZV). Following the resolution of chickenpox, the virus can remain dormant in the dorsal sensory and cranial ganglion for decades. Shingles (herpes zoster [HZ]) is a neurocutaneous disease caused by reactivation of latent VZV and may progress to postherpetic neuralgia (PHN), which is characterized by dermatomal pain persisting for more than 120 days after the onset of HZ rash, or “well-established PHN”, which persist for more than 180 days. Vaccination with an attenuated form of VZV activates specific T-cell production, thereby avoiding viral reactivation and development of HZ. It has been demonstrated to reduce the occurrence by approximately 50−70%, the duration of pain of HZ, and the frequency of subsequent PHN in individuals aged ≥ 50 years in clinical studies. However, it has not proved efficacious in preventing repeat episodes of HZ and reducing the severity of PHN, nor has its long-term efficacy been demonstrated. The most frequent adverse reactions reported for HZ vaccination were injection site pain and/or swelling and headache. In addition, it should not be administrated to children, pregnant women, and immunocompromised persons or those allergic to neomycin or any component of the vaccine.
Abstract
Varicella (chickenpox) is a highly contagious airborne disease caused by primary infection with the varicella zoster virus (VZV). Following the resolution of chickenpox, the virus can remain dormant in the dorsal sensory and cranial ganglion for decades. Shingles (herpes zoster [HZ]) is a neurocutaneous disease caused by reactivation of latent VZV and may progress to postherpetic neuralgia (PHN), which is characterized by dermatomal pain persisting for more than 120 days after the onset of HZ rash, or “well-established PHN”, which persist for more than 180 days. Vaccination with an attenuated form of VZV activates specific T-cell production, thereby avoiding viral reactivation and development of HZ. It has been demonstrated to reduce the occurrence by approximately 50−70%, the duration of pain of HZ, and the frequency of subsequent PHN in individuals aged ≥ 50 years in clinical studies. However, it has not proved efficacious in preventing repeat episodes of HZ and reducing the severity of PHN, nor has its long-term efficacy been demonstrated. The most frequent adverse reactions reported for HZ vaccination were injection site pain and/or swelling and headache. In addition, it should not be administrated to children, pregnant women, and immunocompromised persons or those allergic to neomycin or any component of the vaccine.
참고문헌 (22)
- De Clercq E, "Antivirals: past, present and future", Biochem Pharmacol, 85, pp.727~744 (2013)
- Gershon AA, "Advances in the understanding of the pathogenesis and epidemiology of herpes zoster", J Clin Virol, 48(Suppl 1), pp.S2~S7 (2010)
- Kinchington PR, "Herpes simplex virus and varicella zoster virus, the house guests who never leave", Herpesviridae, 3, pp.5~ (2012)
- Quinlivan M, "Molecular studies of varicella zoster virus", Rev Med Virol, 16, pp.225~250 (2006)
- Temin HM, "RNA-directed DNA synthesis and RNA tumor viruses", Adv Virus Res, 17, pp.129~186 (1972)
- Quinlivan M, "Molecular and therapeutic aspects of varicella-zoster virus infection", Expert Rev Mol Med, 7, pp.1~24 (2005)
- Weigle KA, "Molecular dissection of the humoral immune response to individual varicella-zoster viral proteins during chickenpox, quiescence, reinfection, and reactivation", J Infect Dis, 149, pp.741~749 (1984)
- Arvin AM, "Immunologic evidence of reinfection with varicella-zoster virus", J Infect Dis, 148, pp.200~205 (1983)
- Gershon AA, "Clinical reinfection with varicella-zoster virus", J Infect Dis, 149, pp.137~142 (1984)
- Johnson JA, "Varicella reinfection in a seropositive physician following occupational exposure to localized zoster", Clin Infect Dis, 52, pp.907~909 (2011)
- Thakur R, "Herpes zoster and postherpetic neuralgia, In Bonica’s management of pain. 4th ed", pp.338~357 (2010), Lippincott Williams & Wilkins
- Flatt A, "Varicella vaccines", Br Med Bull, 103, pp.115~127 (2012)
- Reynolds MA, "The impact of the varicella vaccination program on herpes zoster epidemiology in the United States: a review", J Infect Dis, 197(Suppl 2), pp.S224~S227 (2008)
- Goldman GS, "Review of the United States universal varicella vaccination program: herpes zoster incidence rates, cost-effectiveness, and vaccine efficacy based primarily on the Antelope Valley Varicella Active Surveillance Project data", Vaccine, 31, pp.1680~1694 (2013)
- Hambleton S, "Risk of herpes zoster in adults immunized with varicella vaccine", J Infect Dis, 197(Suppl 2), pp.S196~S199 (2008)
- Goldman GS, "Universal varicella vaccination: efficacy trends and effect on herpes zoster", Int J Toxicol, 24, pp.205~213 (2005)
- Goldman GS, "Cost-benefit analysis of universal varicella vaccination in the U.S. taking into account the closely related herpes-zoster epidemiology", Vaccine, 23, pp.3349~3355 (2005)
- Oxman MN, "A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults", N Engl J Med, 352, pp.2271~2284 (2005)
- Schmader KE, "Efficacy, safety, and tolerability of herpes zoster vaccine in persons aged 50-59 years", Clin Infect Dis, 54, pp.922~928 (2012)
- Shapiro M, "Update on herpes zoster vaccination: a family practitioner's guide", Can Fam Physician, 57, pp.1127~1131 (2011)
- Francis Sahngun Nahm, "Survey on the Treatment of Postherpetic Neuralgia in Korea; Multicenter Study of 1,414 Patients", The Korean Journal of Pain, 26(1), pp.21~26 (2013), 대한통증학회
- Gagliardi AM, "Vaccines for preventing herpes zoster in older adults", Cochrane Database Syst Rev, 10, pp.CD008858~ (2012)